Is Hydralazine a Beta Blocker? A Look at How They Differ

Hydralazine is not a beta blocker. The two belong to entirely separate drug classes, lower blood pressure through different mechanisms, produce different side effects, and are prescribed for overlapping but distinct clinical situations. Hydralazine is a direct-acting vasodilator that relaxes arterial smooth muscle, while beta blockers work by blocking adrenaline’s effects on the heart and blood vessels. The confusion likely stems from the fact that both are used to treat high blood pressure, and they are sometimes prescribed together precisely because they complement each other’s weaknesses.

How Hydralazine Works

Hydralazine lowers blood pressure by acting directly on the walls of arteries. It relaxes arterial smooth muscle, which widens resistance arterioles and reduces the force the heart has to pump against. It does this without any dilating effect on veins.¹ The result is a straightforward drop in blood pressure driven entirely by the arteries opening up.

At the cellular level, hydralazine interferes with calcium signaling inside smooth muscle cells. Muscle contraction in blood vessel walls depends on a rise in intracellular calcium concentration. Hydralazine blocks the release of calcium from internal storage sites and also reduces calcium flowing into the cell from outside.² Research in rabbit arteries found that the main action appears to be inhibiting calcium release triggered by a signaling molecule called IP3, which acts on an internal calcium store called the sarcoplasmic reticulum.³ What hydralazine does not do is touch any receptor on the heart. It has no direct effect on how fast the heart beats or how hard it squeezes. Its target is the blood vessel wall, full stop.

How Beta Blockers Work

Beta blockers take a completely different approach. They block beta-adrenergic receptors, which are the docking sites where adrenaline and noradrenaline land to speed up the heart, increase its pumping force, and trigger other stress responses. By occupying those receptors without activating them, beta blockers slow the heart rate, reduce the force of each heartbeat, and lower the amount of blood the heart pushes out per minute. That combination brings blood pressure down.

The class was developed originally to treat angina and heart rhythm problems, and beta blockers have since expanded into treatments for hypertension, heart failure, glaucoma, migraine, and anxiety.⁴ Within the class, individual drugs vary considerably. Some are more selective for the heart’s beta-1 receptors, while others also block beta-2 receptors in the lungs and blood vessels. Some are fat-soluble enough to cross into the brain, while water-soluble versions largely stay out of the central nervous system.⁵ A highly fat-soluble beta blocker like propranolol enters the brain much more readily than a water-soluble one like sotalol, which partly explains why some members of the class are more likely to cause sleep disturbances or vivid dreams.⁶

Why Confusing Them Matters

The distinction between hydralazine and a beta blocker is not just academic taxonomy. The two drugs produce different effects on the body, carry different risk profiles, and should not be substituted for each other. A person taking a beta blocker gets a slower heart rate, lower cardiac output, and often less anxiety or tremor as side benefits. A person taking hydralazine gets dilated arteries while the heart itself is left unrestricted. In fact, because hydralazine drops blood pressure so quickly by opening arteries, the body’s baroreceptors sense the sudden pressure drop and respond by ramping up heart rate and cardiac output. This reflex tachycardia is one of hydralazine’s most common and noticeable side effects, and it is essentially the opposite of what a beta blocker does.

Research in healthy volunteers has confirmed that hydralazine-induced tachycardia is reflexive, triggered by baroreceptor sensitivity, and can vary dramatically from person to person.⁷ In animal models, the picture is a bit more complicated: hydralazine appears to trigger two opposing reflexes simultaneously, one producing tachycardia and another producing a slowing effect through cardiac stretch receptors, with tachycardia usually winning out.⁸ A patient who thinks hydralazine is “basically the same thing” as their beta blocker could be blindsided by a racing pulse or pounding heartbeat.

Side Effects Compared

The two drug classes have almost no overlap in their characteristic adverse effects, which makes sense given their different mechanisms.

Beta blockers’ most predictable side effects flow directly from blocking adrenaline’s effects. These include abnormally slow heart rate, worsening of asthma or reactive airway disease (because beta-2 receptors in the lungs help keep airways open), cold hands and feet from reduced peripheral circulation, and fatigue.⁹ Their tendency to blunt the heart rate and contractile force can also limit exercise capacity, contributing to feelings of breathlessness and tiredness during physical activity.¹⁰ Whether beta blockers cause depression is debated; an evidence-based review found limited scientific support for some traditionally cited side effects like depression and sexual dysfunction.¹¹

Hydralazine’s side-effect profile looks entirely different. The reflex tachycardia already mentioned is the most immediate concern. Beyond that, hydralazine’s most notorious long-term risk is drug-induced lupus, an autoimmune condition in which the immune system starts attacking the body’s own tissues. Research has shown that hydralazine disrupts a process by which the immune system normally edits out self-reactive antibodies, essentially lowering a safety barrier that keeps autoimmunity in check.¹² Enhanced formation of structures called neutrophil extracellular traps may also contribute to this autoimmune reaction.¹³ Drug-induced lupus from hydralazine typically resolves after stopping the medication, but it can be alarming when it appears, causing joint pain, fever, and skin rashes.

Why They Are Often Prescribed Together

The fact that hydralazine and beta blockers have opposite effects on heart rate is precisely why they pair well. A doctor adding a beta blocker to hydralazine therapy can blunt the reflex tachycardia that hydralazine triggers, getting the blood pressure benefit of arterial dilation without the uncomfortable or potentially dangerous racing heart. This combination was a common strategy before newer antihypertensive classes became first-line treatments.

The pharmacokinetic interaction between them is real, too. Hydralazine can increase the blood levels of certain beta blockers that undergo heavy metabolism in the liver. When researchers gave hydralazine alongside metoprolol, a lipophilic beta blocker with substantial first-pass metabolism, metoprolol’s peak concentration and total exposure rose significantly. The same did not happen with beta blockers that are cleared differently.¹⁴ This means a doctor pairing the two needs to know which beta blocker is involved, because the interaction is not uniform across the class.

Genetics and Hydralazine Metabolism

One area where hydralazine stands apart from most beta blockers is how dramatically your genetics can affect the drug’s behavior. Hydralazine is broken down by an enzyme called NAT2, and roughly half the general population carries gene variants that make them “slow acetylators,” meaning they break the drug down much more slowly than the other half.¹⁵ Slow acetylators absorb about two to three times as much active hydralazine from the same oral dose compared to rapid acetylators. One pharmacokinetic review estimated that slow acetylators have a mean bioavailability around 30 to 35 percent, while rapid acetylators see only about 10 to 16 percent of the drug reach their bloodstream.¹⁶

This is not a trivial difference. Slow acetylators are more likely to get a stronger blood-pressure-lowering effect from the same dose, but they are also more vulnerable to adverse effects, including the drug-induced lupus mentioned earlier. A 2025 pharmacogenomics guideline from the Clinical Pharmacogenetics Implementation Consortium formalized this relationship, noting that NAT2 poor metabolizers are predicted to have higher plasma hydralazine levels that can lead to both increased efficacy and increased risk of side effects including lupus.¹⁷ Beta blockers have their own pharmacokinetic variability driven by liver enzyme differences, but the swing in drug levels from the NAT2 polymorphism is especially stark with hydralazine.

Hydralazine’s Niche in Heart Failure

Beta blockers are a cornerstone of modern heart failure treatment. Their role in slowing the heart, reducing adrenaline-driven damage, and improving survival is well established. Hydralazine, by contrast, has a more specialized role in heart failure, and it arrives there through a completely different pathway.

A landmark trial in Black patients with advanced heart failure found that adding a fixed-dose combination of hydralazine and isosorbide dinitrate (a nitrate that dilates veins) to standard therapy, which already included beta blockers and other neurohormonal blockers, reduced death from any cause by about 43 percent compared to placebo. The trial was stopped early because the difference was so large: the mortality rate was roughly 6 percent in the active treatment group versus about 10 percent in the placebo group, along with a one-third reduction in first hospitalization for heart failure.¹⁸ The combination’s benefit is thought to relate to nitric oxide bioavailability and vascular function rather than to any beta-blocking action. In this context, hydralazine is not replacing beta blockers; it is stacked on top of them to address a distinct pathophysiological problem.

Severe Hypertension in Pregnancy

Pregnancy is one clinical scenario where both hydralazine and a beta blocker (specifically labetalol, which has both alpha- and beta-blocking properties) are used head-to-head for the same emergency: severe gestational hypertension or preeclampsia. Both are given intravenously in urgent situations when blood pressure needs to come down fast to protect the mother and baby.

The head-to-head evidence is mixed and depends on which outcomes you prioritize. One trial found that intravenous hydralazine brought blood pressure to target faster, in an average of about 46 minutes versus about 73 minutes for labetalol, and required fewer doses. However, hydralazine caused more maternal side effects like palpitations and tachycardia.¹⁹ Another trial confirmed significantly more palpitations and tachycardia in the hydralazine group, but found that neonatal hypotension and bradycardia were more common in babies whose mothers received labetalol, reflecting the beta blocker’s ability to cross the placenta and slow the fetal heart.²⁰ A third study found labetalol achieved target blood pressure with a single dose in a higher percentage of cases and did so faster than hydralazine, with comparable maternal and fetal outcomes.²¹

The inconsistency across trials reflects real clinical complexity: dosing protocols vary, populations differ, and the tradeoffs between maternal tachycardia (more common with hydralazine) and neonatal heart slowing (more common with labetalol) depend on the situation. Neither drug has clearly won this debate, and many guidelines still list both as acceptable first-line options. What the evidence does make clear is that the two drugs behave differently in this setting in ways that matter for both mother and baby, reinforcing that they are mechanistically distinct agents even when used for the same emergency.

A Less-Known Property of Hydralazine

Beyond its established role as a blood pressure drug, hydralazine has attracted interest for an unexpected biological effect: it can trigger the production of new blood vessels. Research found that hydralazine activates a transcription factor called HIF-1α, which is the body’s master switch for responding to low oxygen. When HIF-1α is turned on, it drives the production of vascular endothelial growth factor, a protein that promotes the growth of new blood vessels. Hydralazine achieves this by inhibiting enzymes called prolyl hydroxylases, which normally mark HIF-1α for destruction.²² This property has nothing to do with beta blockade or even with hydralazine’s primary blood-pressure-lowering mechanism. It represents a completely separate pharmacological action that has sparked interest in areas like wound healing and tissue repair, though clinical applications remain largely investigational. It is one more reminder that hydralazine is its own drug with its own biology, not a variation on the beta blocker theme.